1. Product Overview
2. Research Methodology
3. Impact of COVID-19
on Global Gastric Cancer Therapeutics Market
4.
Executive Summary
5. Voice of Customer
6. Global Gastric
Cancer Therapeutics Market Outlook
6.1.
Market Size & Forecast
6.1.1.
By Value
6.2.
Market Share & Forecast
6.2.1. By Therapy Type (Chemotherapy,
Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery)
6.2.2. By Disease
Indication (Gastric Adenocarcinoma, Gastrointestinal Stromal Tumor (GIST), Gastric
Neuroendocrine Tumors (gNET))
6.2.3. By Molecule Type
(Small Molecule, Biologics)
6.2.4. By Line of Therapy
(Neoadjuvant and Adjuvant, First Line Therapy, Second Line Therapy)
6.2.5. By Mode of Action (Programmed
Cell Death Protein 1 (PD-1) Inhibitors, Human Epidermal Growth Factor Receptor
(HER2) Antagonists, Vascular Endothelial Growth Factor Receptor (VEGFR)
Antagonists, Others (Microtubule Inhibitors, Kinase Inhibitors))
6.2.6. By Route of
Administration (Oral vs. Parenteral)
6.2.7. By End User
(Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
6.2.8. By Distribution
channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
6.2.9. By Company (2021)
6.2.10. By
Region
6.3. Product
Market Map
7. Asia-Pacific Gastric
Cancer Therapeutics Market Outlook
7.1.
Market Size & Forecast
7.1.1.
By Value
7.2.
Market Share & Forecast
7.2.1. By Therapy Type
7.2.2. By Disease
Indication
7.2.3. By Molecule Type
7.2.4. By Line of Therapy
7.2.5. By Mode of Action
7.2.6. By Route of
Administration
7.2.7. By End User
7.2.8. By Distribution
Channel
7.2.9.
By Country
7.3.
Asia-Pacific: Country Analysis
7.3.1.
China Gastric Cancer Therapeutics Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Therapy Type
7.3.1.2.2.
By Disease Indication
7.3.1.2.3.
By Molecule Type
7.3.1.2.4.
By Line of Therapy
7.3.1.2.5.
By Mode of Action
7.3.1.2.6.
By Route of Administration
7.3.1.2.7.
By End User
7.3.1.2.8.
By Distribution Channel
7.3.2.
India Gastric Cancer Therapeutics Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Therapy Type
7.3.2.2.2.
By Disease Indication
7.3.2.2.3.
By Molecule Type
7.3.2.2.4.
By Line of Therapy
7.3.2.2.5.
By Mode of Action
7.3.2.2.6.
By Route of Administration
7.3.2.2.7.
By End User
7.3.2.2.8.
By Distribution Channel
7.3.3.
Japan Gastric Cancer Therapeutics Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Therapy Type
7.3.3.2.2.
By Disease Indication
7.3.3.2.3.
By Molecule Type
7.3.3.2.4.
By Line of Therapy
7.3.3.2.5.
By Mode of Action
7.3.3.2.6.
By Route of Administration
7.3.3.2.7.
By End User
7.3.3.2.8.
By Distribution Channel
7.3.4.
South Korea Gastric Cancer Therapeutics Market Outlook
7.3.4.1.
Market Size & Forecast
7.3.4.1.1.
By Value
7.3.4.2.
Market Share & Forecast
7.3.4.2.1.
By Therapy Type
7.3.4.2.2.
By Disease Indication
7.3.4.2.3.
By Molecule Type
7.3.4.2.4.
By Line of Therapy
7.3.4.2.5.
By Mode of Action
7.3.4.2.6.
By Route of Administration
7.3.4.2.7.
By End User
7.3.4.2.8.
By Distribution Channel
7.3.5.
Australia Gastric Cancer Therapeutics Market Outlook
7.3.5.1.
Market Size & Forecast
7.3.5.1.1.
By Value
7.3.5.2.
Market Share & Forecast
7.3.5.2.1.
By Therapy Type
7.3.5.2.2.
By Disease Indication
7.3.5.2.3.
By Molecule Type
7.3.5.2.4.
By Line of Therapy
7.3.5.2.5.
By Mode of Action
7.3.5.2.6.
By Route of Administration
7.3.5.2.7.
By End User
7.3.5.2.8.
By Distribution Channel
8. Europe Gastric
Cancer Therapeutics Market Outlook
8.1.
Market Size & Forecast
8.1.1.
By Value
8.2.
Market Share & Forecast
8.2.1. By Therapy Type
8.2.2. By Disease
Indication
8.2.3. By Molecule Type
8.2.4. By Line of Therapy
8.2.5. By Mode of Action
8.2.6. By Route of
Administration
8.2.7. By End User
8.2.8. By Distribution
Channel
8.2.9.
By Country
8.3.
Europe: Country Analysis
8.3.1.
France Gastric Cancer Therapeutics Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Therapy Type
8.3.1.2.2.
By Disease Indication
8.3.1.2.3.
By Molecule Type
8.3.1.2.4.
By Line of Therapy
8.3.1.2.5.
By Mode of Action
8.3.1.2.6.
By Route of Administration
8.3.1.2.7.
By End User
8.3.1.2.8.
By Distribution Channel
8.3.2.
Germany Gastric Cancer Therapeutics Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Therapy Type
8.3.2.2.2.
By Disease Indication
8.3.2.2.3.
By Molecule Type
8.3.2.2.4.
By Line of Therapy
8.3.2.2.5.
By Mode of Action
8.3.2.2.6.
By Route of Administration
8.3.2.2.7.
By End User
8.3.2.2.8.
By Distribution Channel
8.3.3.
United Kingdom Gastric Cancer Therapeutics Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Therapy Type
8.3.3.2.2.
By Disease Indication
8.3.3.2.3.
By Molecule Type
8.3.3.2.4.
By Line of Therapy
8.3.3.2.5.
By Mode of Action
8.3.3.2.6.
By Route of Administration
8.3.3.2.7.
By End User
8.3.3.2.8.
By Distribution Channel
8.3.4.
Italy Gastric Cancer Therapeutics Market Outlook
8.3.4.1.
Market Size & Forecast
8.3.4.1.1.
By Value
8.3.4.2.
Market Share & Forecast
8.3.4.2.1.
By Therapy Type
8.3.4.2.2.
By Disease Indication
8.3.4.2.3.
By Molecule Type
8.3.4.2.4.
By Line of Therapy
8.3.4.2.5.
By Mode of Action
8.3.4.2.6.
By Route of Administration
8.3.4.2.7.
By End User
8.3.4.2.8.
By Distribution Channel
8.3.5.
Spain Gastric Cancer Therapeutics Market Outlook
8.3.5.1.
Market Size & Forecast
8.3.5.1.1.
By Value
8.3.5.2.
Market Share & Forecast
8.3.5.2.1.
By Therapy Type
8.3.5.2.2.
By Disease Indication
8.3.5.2.3.
By Molecule Type
8.3.5.2.4.
By Line of Therapy
8.3.5.2.5.
By Mode of Action
8.3.5.2.6.
By Route of Administration
8.3.5.2.7.
By End User
8.3.5.2.8.
By Distribution Channel
9. North America Gastric
Cancer Therapeutics Market Outlook
9.1.
Market Size & Forecast
9.1.1.
By Value
9.2.
Market Share & Forecast
9.2.1. By Therapy Type
9.2.2. By Disease
Indication
9.2.3. By Molecule Type
9.2.4. By Line of Therapy
9.2.5. By Mode of Action
9.2.6. By Route of
Administration
9.2.7. By End User
9.2.8. By Distribution
Channel
9.2.9.
By Country
9.3.
North America: Country Analysis
9.3.1.
United States Gastric Cancer Therapeutics Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Therapy Type
9.3.1.2.2.
By Disease Indication
9.3.1.2.3.
By Molecule Type
9.3.1.2.4.
By Line of Therapy
9.3.1.2.5.
By Mode of Action
9.3.1.2.6.
By Route of Administration
9.3.1.2.7.
By End User
9.3.1.2.8.
By Distribution Channel
9.3.2.
Mexico Gastric Cancer Therapeutics Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Therapy Type
9.3.2.2.2.
By Disease Indication
9.3.2.2.3.
By Molecule Type
9.3.2.2.4.
By Line of Therapy
9.3.2.2.5.
By Mode of Action
9.3.2.2.6.
By Route of Administration
9.3.2.2.7.
By End User
9.3.2.2.8.
By Distribution Channel
9.3.3.
Canada Gastric Cancer Therapeutics Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Therapy Type
9.3.3.2.2.
By Disease Indication
9.3.3.2.3.
By Molecule Type
9.3.3.2.4.
By Line of Therapy
9.3.3.2.5.
By Mode of Action
9.3.3.2.6.
By Route of Administration
9.3.3.2.7.
By End User
9.3.3.2.8.
By Distribution Channel
10. South America Gastric
Cancer Therapeutics Market Outlook
10.1.
Market Size & Forecast
10.1.1.
By Value
10.2.
Market Share & Forecast
10.2.1. By Therapy Type
10.2.2. By Disease
Indication
10.2.3. By Molecule Type
10.2.4. By Line of Therapy
10.2.5. By Mode of Action
10.2.6. By Route of
Administration
10.2.7. By End User
10.2.8. By Distribution
Channel
10.2.9.
By Country
10.3.
South America: Country Analysis
10.3.1.
Brazil Gastric Cancer Therapeutics Market Outlook
10.3.1.1.
Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2.
Market Share & Forecast
10.3.1.2.1.
By Therapy Type
10.3.1.2.2.
By Disease Indication
10.3.1.2.3.
By Molecule Type
10.3.1.2.4.
By Line of Therapy
10.3.1.2.5.
By Mode of Action
10.3.1.2.6.
By Route of Administration
10.3.1.2.7.
By End User
10.3.1.2.8.
By Distribution Channel
10.3.2.
Argentina Gastric Cancer Therapeutics Market Outlook
10.3.2.1.
Market Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2.
Market Share & Forecast
10.3.2.2.1.
By Therapy Type
10.3.2.2.2.
By Disease Indication
10.3.2.2.3.
By Molecule Type
10.3.2.2.4.
By Line of Therapy
10.3.2.2.5.
By Mode of Action
10.3.2.2.6.
By Route of Administration
10.3.2.2.7.
By End User
10.3.2.2.8.
By Distribution Channel
10.3.3.
Colombia Gastric Cancer Therapeutics Market Outlook
10.3.3.1.
Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2.
Market Share & Forecast
10.3.3.2.1.
By Therapy Type
10.3.3.2.2.
By Disease Indication
10.3.3.2.3.
By Molecule Type
10.3.3.2.4.
By Line of Therapy
10.3.3.2.5.
By Mode of Action
10.3.3.2.6.
By Route of Administration
10.3.3.2.7.
By End User
10.3.3.2.8.
By Distribution Channel
11. Middle East and
Africa Gastric Cancer Therapeutics Market Outlook
11.1.
Market Size & Forecast
11.1.1.
By Value
11.2.
Market Share & Forecast
11.2.1. By Therapy Type
11.2.2. By Disease
Indication
11.2.3. By Molecule Type
11.2.4. By Line of Therapy
11.2.5. By Mode of Action
11.2.6. By Route of
Administration
11.2.7. By End User
11.2.8. By Distribution
Channel
11.2.9.
By Country
11.3.
MEA: Country Analysis
11.3.1.
South Africa Gastric Cancer Therapeutics Market Outlook
11.3.1.1.
Market Size & Forecast
11.3.1.1.1.
By Value
11.3.1.2.
Market Share & Forecast
11.3.1.2.1.
By Therapy Type
11.3.1.2.2.
By Disease Indication
11.3.1.2.3.
By Molecule Type
11.3.1.2.4.
By Line of Therapy
11.3.1.2.5.
By Mode of Action
11.3.1.2.6.
By Route of Administration
11.3.1.2.7.
By End User
11.3.1.2.8.
By Distribution Channel
11.3.2.
Saudi Arabia Gastric Cancer Therapeutics Market Outlook
11.3.2.1.
Market Size & Forecast
11.3.2.1.1.
By Value
11.3.2.2.
Market Share & Forecast
11.3.2.2.1.
By Therapy Type
11.3.2.2.2.
By Disease Indication
11.3.2.2.3.
By Molecule Type
11.3.2.2.4.
By Line of Therapy
11.3.2.2.5.
By Mode of Action
11.3.2.2.6.
By Route of Administration
11.3.2.2.7.
By End User
11.3.2.2.8.
By Distribution Channel
11.3.3.
UAE Gastric Cancer Therapeutics Market Outlook
11.3.3.1.
Market Size & Forecast
11.3.3.1.1.
By Value
11.3.3.2.
Market Share & Forecast
11.3.3.2.1.
By Therapy Type
11.3.3.2.2.
By Disease Indication
11.3.3.2.3.
By Molecule Type
11.3.3.2.4.
By Line of Therapy
11.3.3.2.5.
By Mode of Action
11.3.3.2.6.
By Route of Administration
11.3.3.2.7.
By End User
11.3.3.2.8.
By Distribution Channel
12. Market Dynamics
12.1.
Drivers
12.2.
Challenges
13. Market Trends &
Developments
14. Clinical Trial Analysis
15. Competitive
Landscape
15.1.
Competition Outlook
15.2.
Players Profiled
15.2.1.
Bristol-Myers Squibb
AB
15.2.2.
Celltrion Inc.
15.2.3.
Eli Lilly and
Company
15.2.4.
Hoffmann-La Roche
Ltd.
15.2.5.
GlaxoSmithKline PLC
15.2.6.
Imugene Limited
15.2.7.
Novartis AG
15.2.8.
Merck & Co. Inc.
15.2.9.
Otsuka Holdings Co.
Ltd
15.2.10.
Pfizer Inc.
15.2.11.
Array Biopharma Inc.
15.2.12.
AstraZeneca PLC
15.2.13.
Ipsen
Biopharmaceuticals Ltd.
15.2.14.
Taiho Oncology Inc.
15.2.15.
Galena Biopharma
Inc.
16.
Strategic Recommendations